Výsledky vyhledávání - "JG Sanchez Ramos"

PKP-014 Influence of the genetic polymorphisms on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty

Autor: LM Salmerón-Febres, M Valle Corpas, Luis Javier Martinez-Gonzalez, F Fernández-Quesada, Cristina Lucía Dávila-Fajardo, X Diaz Villamarin, JG Sanchez Ramos, I Casas Hidalgo, Pedro Carmona-Sáez

Publikováno v: European Journal of Hospital Pharmacy. 23:A184.1-A184

Background Clopidogrel has provided a significant reduction in major vascular events in patients with peripheral artery disease in general, and those undergoing percutaneous transluminal balloon angioplasty in particular. At present, it is not possib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9e6a241ce6e37c04baf0d194c95b6139
https://doi.org/10.1136/ejhpharm-2016-000875.417

Zobrazit plný text záznamu

PKP-021 Results of the use of pharmacogenetics in the choice of antiplatelet therapy after percutaneous coronary intervention with stent

Autor: P Toledo Frías, F Burillo Gómez, A Bautista Pavés, C Correa Vilches, JG Sanchez Ramos, X Diaz Villamarin, S Martinez Huertas, LJ Martinez Gonzalez, J Cabeza Barrera, CL Dávila Fajardo

Publikováno v: European Journal of Hospital Pharmacy. 23:A188.1-A188

Background Clopidogrel provides a reduction in cardiovascular events in acute coronary syndrome (ACS) patients, particularly for those who have undergone percutaneous coronary intervention (PCI). The cardiovascular response has been associated with s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8c2ee56845fdd14513b6929c4a081025
https://doi.org/10.1136/ejhpharm-2016-000875.424

Zobrazit plný text záznamu

PKP-003 Pharmacogenetics in antiplatelet treatment with clopidogrel in vascular pathology

Autor: JG Sanchez Ramos, X Diaz Villamarin, LJ Martinez Gonzalez, Mdc Marin, S Martinez Huertas, Francisco V. Fernández, J Cabeza Barrera, CL Dávila Fajardo

Publikováno v: European Journal of Hospital Pharmacy. 22:A132.1-A132

Background Clopidogrel is metabolised by CYP2C19 to the active metabolite responsible for the inhibition of platelet aggregation. The P-glycoprotein encoded by the ABCB1 gene is key in drug absorption. The effects differ according to genotype ABCB1 a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d015799323a1f6678a065298ec2c7824
https://doi.org/10.1136/ejhpharm-2015-000639.319

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání